These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17611572)

  • 41. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.
    Archer GE; Sampson JH; McLendon RE; Friedman AH; Colvin OM; Rose M; Sands H; McCullough W; Fuchs HE; Bigner DD; Friedman HS
    J Neurooncol; 1999; 44(3):233-41. PubMed ID: 10720203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treosulfan as an effective second-line therapy in ovarian cancer.
    Gropp M; Meier W; Hepp H
    Gynecol Oncol; 1998 Oct; 71(1):94-8. PubMed ID: 9784326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan.
    Candoni A; Tiribelli M; Fanin R
    Leuk Lymphoma; 2004 Apr; 45(4):821-4. PubMed ID: 15160964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Primary thrombocythaemia treated with busulphan.
    Van de Pette JE; Prochazka AV; Pearson TC; Singh AK; Dickson ER; Wetherley-Mein G
    Br J Haematol; 1986 Feb; 62(2):229-37. PubMed ID: 3947546
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical case. Primary thrombocythemia].
    Pozzato G; Terpin MM; Rinaldi C; Frezza M
    G Clin Med; 1987 Feb; 68(2):121-3. PubMed ID: 3609602
    [No Abstract]   [Full Text] [Related]  

  • 46. Busulfan in early pregnancy.
    Williams DW
    Obstet Gynecol; 1966 May; 27(5):738-40. PubMed ID: 5220059
    [No Abstract]   [Full Text] [Related]  

  • 47. Platelet dysfunction in essential thrombocythaemia.
    Stathakis NE; Papayannis AG; Arapakis G; Gardikas C
    Ann Clin Res; 1974 Aug; 6(4):198-202. PubMed ID: 4473953
    [No Abstract]   [Full Text] [Related]  

  • 48. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
    Spieth K; Kaufmann R; Gille J
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Essential thrombocythemia].
    Torre López E
    Rev Invest Clin; 1995; 47(1):83-4. PubMed ID: 7777720
    [No Abstract]   [Full Text] [Related]  

  • 50. Thrombocythaemia and multiple myeloma. A report on two cases.
    Selroos O; van Assendelft A
    Acta Med Scand; 1977; 201(3):243-7. PubMed ID: 557871
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Essential thrombocythemia].
    Krupsky M; Berrebi A
    Harefuah; 1987 Mar; 112(6):268-72. PubMed ID: 3609955
    [No Abstract]   [Full Text] [Related]  

  • 53. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
    Ferrara F; Palmieri S; Annunziata M; Viola A; Pocali B; Califano C; D'Arco AM; Mele G
    Bone Marrow Transplant; 2004 Oct; 34(7):573-6. PubMed ID: 15258559
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
    Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
    Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent.
    Bitan M; Or R; Shapira MY; Resnick IB; Ackerstein A; Samuel S; Elad S; Slavin S
    Haematologica; 2005 Aug; 90(8):1089-95. PubMed ID: 16079108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Second malignancies in patients with essential thrombocythaemia.
    Randi ML; Fabris F; Girolami A
    Br J Haematol; 2002 Mar; 116(4):923-4. PubMed ID: 11886403
    [No Abstract]   [Full Text] [Related]  

  • 58. A cautionary tale: how to delete mouse haemopoietic stem cells with busulphan.
    Jopling C; Rosendaal M
    Br J Haematol; 2001 Jun; 113(4):970-4. PubMed ID: 11442491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Busulphan haemorrhagic cystitis.
    Millard RJ
    Br J Urol; 1978 May; 50(3):210. PubMed ID: 288495
    [No Abstract]   [Full Text] [Related]  

  • 60. The dangers of surgery in uncontrolled haemorrhagic thrombocythaemia.
    Ravich RB; Gunz FW; Thompson IL; Reed CS
    Med J Aust; 1970 Apr; 1(14):704-8. PubMed ID: 5464014
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.